Pradaxa

Ensure safety

Familiarize yourself with the results of the GLORIA-AF registry published in 2022

The registry recruited patients over 18 years old, with newly diagnosed NVAF (non-valvular AF) and a CHA2DS2 -VASc score of at least 1. Overall GLORIA-AF delivered data of 21 591 patients observed for over 3 years, enrolled in 935 centres in 38 countries. The median CHA2DS2—VASc score was 3.2 and HAS-BLED score 1.4 indicating a high risk of stroke and low risk of bleeding[1,2].

Are you aware of the latest analysis providing comparison between dabigatran and rivaroxaban, or apixaban?

Compared to apixaban, dabigatran demonstrated non-inferiority in all types of stroke, major bleeding, all-cause death, the risk of myocardial infarction and composite outcome*. When it comes to rivaroxaban, the analysis indicated a 41% relative risk reduction of major bleeding favoring dabigatran[2]:

Footnotes

VKA – vitamin K antagonist

* The composite of stroke, systemic embolism, myocardial infarction, vascular death, and life-threatening bleeding